Decision to Approve First Obesity Drug in a Decade Coming Soon

April 10, 2012
An advisory panel to FDA in February urged approval of Qnexa, after warning against its approval in 2010 due to safety concerns.

U.S. regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.

The extra time is a "standard extension period" offered by the U.S. Food and Drug Administration in order to review additional risk management strategies that were submitted by the company, said a statement issued on April 9.

An advisory panel to FDA in February urged approval of Qnexa, after warning against its approval in 2010 due to safety concerns. The panel voted 20-2 that the FDA should allow Qnexa on the market, saying the latest overall benefit-risk assessment supported its approval, but asking for more data on potential risks and how to avoid them.

For instance, some people who took high doses of the drug experienced increased heart rate. When taken by pregnant women it also boosted the risk of having a baby with cleft palate.

"The Qnexa REMS (risk evaluation and mitigation strategy) submission is comprehensive, with materials based on ongoing feedback from the FDA since our advisory committee meeting in February," said Leland Wilson, chief executive officer of VIVUS.

"We look forward to finalizing our REMS with the FDA while we move forward with our commercialization plans."

Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

Some doctors already prescribe the combination as an off-label use for helping patients manage their weight.

Studies have shown dieters could lose up to 10% of their weight when taking the drug, along with regular exercise and following a healthy diet.

The FDA does not have to follow the advice of the advisory panel, though it usually does.

Copyright Agence France-Presse, 2012

Popular Sponsored Recommendations

Digitally Transforming Data and Processes With Product Lifecycle Management

Oct. 29, 2023
Manufacturers face increasing challenges in product development as they strive to consistently deliver improved results. Discover how industry leaders are improving time-to-market...

Process Mining For Dummies

Nov. 19, 2023
Here it is. Everything you need to know about process mining in a single book, written in the easy-to-understand, hard-to-forget style that ‘For Dummies’ manages so effortlessly...

Are You Positioned To Tackle Supply Chain Risk?

Sept. 20, 2023
Supply chain disruption is here to stay, but you can keep ahead of potential issues — and identify new opportunities — by regularly assessing your suppliers. Download our supplier...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!